Furthermore, engineered bispecific proteins targeting the 4-1BB molecule on T-cells and tumour stroma (FAP-4-1BBL) or tumour antigen (CD19-4-1BBL) have been developed to reduce hepatotoxicity and dependency on FcγR binding (hulgG1PGLALA). Here, CD19 is linked to neoplasm.